Email abimanesh@nus.edu.sg

Abi Manesh is an infectious diseases physician interested in the design and implementation of large-scale, multicentric clinical trials, with a particular emphasis on addressing the unique challenges and perspectives of low- and middle-income countries (LMICs). His research is centered on combating antimicrobial resistance (AMR), a growing global health crisis disproportionately affecting resource-limited settings, and investigating brain infections, including their epidemiology, pathophysiology, and treatment. He focuses on evidence-based interventions that are feasible and impactful in LMIC contexts, aiming to improve patient outcomes and inform public health strategies through collaborative, high-quality clinical research.

• NUS Saw Swee Hock School of Public Health (Visiting)
• Christian Medical College, Vellore

• Antimicrobial resistance
• Brain infections

• Infectious Diseases
• Epidemiology
• Clinical trials

• MBBS, Christian Medical College, Vellore, India
• MD in Internal Medicine, Christian Medical College, Vellore
• DNB in General Medicine, Christian Medical College, Vellore
• DM in Infectious Diseases, Christian Medical College, Vellore

• Early Career Clinical and Public Health Fellow at the Wellcome DBT India Alliance
• Oxford Population Health Studentship, University of Oxford

• 2021 – current: Associate Professor, Christian Medical College, Vellore
• 2019 – 2021: Assistant Professor, Christian Medical College, Vellore
• 2019: Senior Resident, Christian Medical College, Vellore
• 2016 – 2019: Senior Registrar (DM Trainee), Christian Medical College, Vellore
• 2014 – 2016: Assistant Professor, Christian Medical College, Vellore
• 2014: Tutor, Christian Medical College, Vellore
• 2011 – 2014: Registrar (MD Trainee), Christian Medical College, Vellore

• Deputy Medical Superintendent, Christian Medical College, Vellore, India
• Associate Head of Pharmacy, Christian Medical College, Vellore, India

• Joint Treasurer, Clinical Infectious Diseases Society, India

• Inbaraj LR, Manesh A, Ponnuraja C, Bhaskar A, Srinivasalu VA, Daniel BD. Comparative evaluation of intensified short course regimen and standard regimen for adults TB meningitis: a protocol for an open label, multi-center, parallel arms, randomized controlled superiority trial (INSHORT trial). Trials. 2024 May 2;25(1):294. doi: 10.1186/s13063-024-08133-6.
• Manesh A, Gautam P, Kumar D SS, Mannam P, Jasper A, Gunasekaran K, Thomas NC, Benjamin RN, Inbaraj LR, Devasagayam E, George MM, Karthik R, Abraham OC, Vanjare HA, Sivadasan A, Appaswamy PT, Jonathan E, Michael JS, Samuel P, Varghese GM. Effectiveness of Adjunctive High-Dose Infliximab Therapy to Improve Disability-Free Survival Among Patients With Severe Central Nervous System Tuberculosis: A Matched Retrospective Cohort Study. Clin Infect Dis. 2023 Nov 17;77(10):1460-1467.
• Manesh A, Devasagayam E, Bhanuprasad K, Varghese L, Kurien R, Cherian LM, Dayanand D, George MM, Kumar SS, Karthik R, Vanjare H, Peter J, Michael JS,
  Thomas M, Mathew BS, Samuel P, Peerawaranun P, Mukaka M, Rupa V, Varghese GM. Short intravenous amphotericin B followed by oral posaconazole using a simple, stratified treatment approach for diabetes or COVID-19-associated rhino-orbito- cerebral mucormycosis: a prospective cohort study. Clin Microbiol Infect. 2023 Oct;29(10):1298-1305.
• Manesh A, Devasagayam E, Bhanuprasad K, Mathew SK, Karthik R, Mathew BS, Varghese GM. Efficacy of Crushed Delayed-Release Posaconazole Tablets in Rhino- Orbito-Cerebral Mucormycosis. Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0108522.
• Manesh A, Varghese GM; CENDRIC Investigators and Collaborators. Rising antimicrobial resistance: an evolving epidemic in a pandemic. Lancet Microbe. 2021 Sep;2(9):e419-e420.
• Manesh A, Devasagayam E, Sahu S, Bhanuprasad K, Mannam P, Karthik R, Varghese GM. Primary odontogenic onset invasive mucormycosis-an under recognized clinical entity. Clin Microbiol Infect. 2023 Aug;29(8):1086.e1-1086.e5.
• Bhanuprasad K, Manesh A, Devasagayam E, Varghese L, Cherian LM, Kurien R, Karthik R, Deodhar D, Vanjare H, Peter J, Michael JS, Thomas M, Samuel P, Varghese GM. Risk factors associated with the mucormycosis epidemic during the COVID-19 pandemic. Int J Infect Dis. 2021 Oct;111:267-270. doi:
  10.1016/j.ijid.2021.08.037.
• Manesh A, Barnabas R, Mani S, Karthik R, Abraham OC, Chacko G, Kannangai R, Varghese GM. Symptomatic HIV CNS viral escape among patients on effective cART. Int J Infect Dis. 2019 Jul;84:39-43.
• Manesh A, Shankar C, George MM, Jasrotia DS, Lal B, George B, Mathews V, Eapen CE, Joseph P, Subramani K, Rao S, Peter JV, Chacko B, Zachariah A, Sathyendra S, Hansdak SG, Abraham OC, Iyadurai R, Vijayakumar S, Karthik R, Marwick CA, Parcell BJ, Gilbert IH, Veeraraghavan B, Varghese GM. Clinical and Genomic Evolution of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections over Two Time Periods at a Tertiary Care Hospital in South India: A Prospective Cohort Study. Infect Dis Ther. 2023 May;12(5):1319-1335.
• Manesh A, George MM, Bhanuprasad K, John GM, Korula A, Abraham A, Mathews V, Kulkarni UP, Shankar C, Premkumar PS, Chacko B, Subramani K, Varghese GM, Balaji V, George B. Persistent bacteremia predicts poor outcomes among neutropenic patients with carbapenem-resistant gram-negative bloodstream infections receiving appropriate therapy. Ann Clin Microbiol Antimicrob. 2023 Feb 15;22(1):12.
• Manesh A, George MM, Palanikumar P, Nagaraj V, Bhanuprasad K, Krishnan R, Nivetha G, Lal B, Triveni KR, Gautam P, George B, Kulkarni U, Mathews V, Subramani K, Rao S, Chacko B, Zachariah A, Sathyendra S, Hansdak SG, Abraham OC, Iyadurai R, Karthik R, Peter JV, Mo Y, Veeraraghavan B, Varghese GM, Paterson DL. Combination Versus Monotherapy for Carbapenem-Resistant Acinetobacter Species Serious Infections: A Prospective IPTW Adjusted Cohort Study. Infect Dis Ther. 2024 Nov;13(11):2351-2362.